Technical Analysis for PRVB - Provention Bio, Inc.

Grade Last Price % Change Price Change
grade D 6.04 3.07% 0.18
PRVB closed up 3.07 percent on Tuesday, October 15, 2019, on 57 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Oct 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Flat Down Down
See historical PRVB trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish 3.07%
Wide Bands Range Expansion 3.07%
Oversold Stochastic Weakness 3.07%
Slingshot Bearish Bearish Swing Setup -0.17%
Bullish Engulfing Bullish -0.17%
Crossed Above 200 DMA Bullish -0.17%
Wide Bands Range Expansion -0.17%

Older signals for PRVB ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.
Medicine Biopharmaceutical Medical Specialties Immunology Disease Diabetes Autoimmune Diseases Ulcerative Colitis Abdominal Pain Diarrhea Crohn's Disease Colitis Lupus Viral Diseases Immune Mediated Diseases
Is PRVB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 22.82
52 Week Low 1.52
Average Volume 457,946
200-Day Moving Average 6.0339
50-Day Moving Average 8.7025
20-Day Moving Average 7.3243
10-Day Moving Average 6.4835
Average True Range 0.6557
ADX 32.95
+DI 12.1676
-DI 30.8395
Chandelier Exit (Long, 3 ATRs ) 8.1329
Chandelier Exit (Short, 3 ATRs ) 7.5771
Upper Bollinger Band 9.4751
Lower Bollinger Band 5.1735
Percent B (%b) 0.2
BandWidth 58.730527
MACD Line -0.8849
MACD Signal Line -0.7902
MACD Histogram -0.0947
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.72
Resistance 3 (R3) 6.72 6.49 6.60
Resistance 2 (R2) 6.49 6.32 6.49 6.56
Resistance 1 (R1) 6.27 6.22 6.38 6.27 6.53
Pivot Point 6.04 6.04 6.10 6.04 6.04
Support 1 (S1) 5.82 5.87 5.93 5.82 5.55
Support 2 (S2) 5.59 5.77 5.59 5.52
Support 3 (S3) 5.37 5.59 5.48
Support 4 (S4) 5.37